Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma - LARVOL DELTA

Conservative and newer drug treatment for degenerative cervical myelopathy. (PubMed, J Clin Orthop Trauma) - "Riluzole did not replicate its promising animal results in human trials, using the modified Japanese Orthopaedic Association (mJOA) score as an outcome measure. Cerebrolysin is promising but needs more RCTs to define its role in the management algorithm. Limaprost Alfadex provided inconclusive evidence, however, is in an ongoing phase III trial...Anti-Fas ligand antibody has not been studied in humans but demonstrated benefit in animal models. Research should focus on large-scale RCTs for these drugs with careful attention to long-term effects, side effects, and finding the most effective doses."

Journal • CNS Disorders • Infectious Disease • Inflammation • Orthopedics • FASLG

CLINCH: Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial (clinicaltrials.gov) - P4 | N=30 | Not yet recruiting | Sponsor: Cardinal Stefan Wyszynski University

New P4 trial • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders

Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Yonsei University

New P4 trial • Cardiovascular

Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "AT may be safely resumed within 48 h in low-risk patients (HTI=0), on days 3-5 in high-risk patients (HTI=1-4), and on day 10 in very-high-risk patients (HTI=5-8) without symptomatic HT. Cerebrolysin mitigates the compounding effect, reduces HT risk, and facilitates earlier, safer AT resumption in high-risk patients (HTI=1-4) by day 2 post-stroke, supporting its role in personalized stroke management."

Clinical • Journal • Retrospective data • Cardiovascular • Hematological Disorders

Cerebrolysin Induces Dendritic Tree Plastic Changes and BDNF Increase in the Amygdala of Male Rats with Maternal Deprivation. (PubMed, Neurochem Res) - "Our results show that CBL could be part of the treatment in case of a traumatic or stressful event in neurodevelopment, especially in the youth age. According to this preclinical study, CBL could help reverse symptoms of different psychopathologies caused by stress or trauma, with neurobiological changes underlying its effect."

Journal • Preclinical • Mood Disorders • BDNF

Update on Neuroprotection after Traumatic Brain Injury. (PubMed, CNS Drugs) - "New strategies and pharmacotherapy options for neuroprotection continue to be evaluated, including tranexamic acid, progesterone, cerebrolysin, cyclosporin A, citicholine, memantine, and lactate. The spectrum of TBI severity has also gained increasing attention as it relates to mild TBI or concussion, blast injury, and subacute or chronic subdural hematomas. In this review, we review the pathophysiology, recent clinical trials, and future directions for acute TBI."

Journal • Review • CNS Disorders • Vascular Neurology

Retraction Note: Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. (PubMed, BMC Neurosci) - No abstract available

Journal • Frontotemporal Lobar Degeneration

Drug-Induced Alteration of Hair Pigmentation: a clinical review and update (AAD 2025) - " Hypopigmentation of the hair, including graying/whitening has been reported with anticonvulsants, interferons, retinoids, tyrosine kinase inhibitors, chemotherapy agents, chloroquine, and hydroxychloroquine. Hair darkening has been reported with cholinesterase inhibitors, retinoids, minoxidil, hormone analogs, prostaglandin analogs, immunomodulatory and immunosuppressive medications. Repigmentation of previously gray hair has been associated with monoclonal antibodies, tyrosine kinase inhibitors, retinoids, tamoxifen, cerebrolysin, and topical pseudocatalase...Three cases of permanent/persistent hair color change have been reported with brentuximab, dupilumab, and a cholinesterase inhibitor. A wide range of medications can induce permanent or temporary alterations of hair pigmentation, and subsequently impact medication adherence and quality of life. Updated knowledge and comprehensive understanding of the medications associated with drug-induced hair color changes is..."

Clinical • Review • CAT

Cerebrolysin as an adjuvant therapy after mechanical thrombectomy in large vessel occlusion cardioembolic stroke: a propensity score matching analysis. (PubMed, Front Neurol) - "The administration of Cerebrolysin was safe and well tolerated. Further studies are required to confirm these results."

Journal • Cardiovascular • Hematological Disorders • Ischemic stroke

C-REGS2: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness (clinicaltrials.gov) - P=N/A | N=1851 | Completed | Sponsor: Ever Neuro Pharma GmbH | Active, not recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Jul 2024

HEOR • Trial completion • Trial completion date • Cardiovascular • Ischemic stroke

CERICA: CERebrolysin in CADASIL (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Ever Neuro Pharma GmbH | Recruiting ➔ Active, not recruiting

Enrollment closed

Effect of neurofeedback training on relative α variant score monitored by bedside continuous electroencephalography and optic nerve sheath diameter evaluated by ultrasound in patients with ischemic hypoxic encephalopathy (PubMed, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue) - "Both ONDS determined by ultrasound and relative α variation score monitored by electroencephalography changed significantly in the patients with ischemic hypoxic encephalopathy. Neurofeedback training can effectively improve brain function in patients with ischemic hypoxic encephalopathy."

Journal • Observational data • Cardiovascular • CNS Disorders • Critical care • Depression • Psychiatry • BDNF

Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. (PubMed, Stroke) - "Further research with larger cohorts is needed to fully establish the efficacy of this combination therapy. URL: https://www.isrctn.com; Unique identifier: ISRCTN54581790."

Journal • Cardiovascular • Ischemic stroke

Correction to: Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. (PubMed, Stroke) - No abstract available

Journal • Cardiovascular

Importance of Modulating Kynurenic Acid Metabolism-Approaches for the Treatment of Dementia. (PubMed, Biomolecules) - "The newly developed Helix pomatia snail model of memory can be used for the assessment of novel pharmacological approaches. Dietary supplementation with natural molecular/herbal extracts, exercise, and physical activity have significant impacts on endogenous pharmacology by reducing kynurenic acid synthesis, and these factors are likely to significantly modulate steady-state biological conditions and delay the negative consequences of aging, including the onset of pathological processes."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Mental Retardation • Psychiatry

Cerebrolysin treatment improved short-term memory deficits while simultaneously increasing hippocampal spine density in hypertensive female rats. (PubMed, Behav Brain Res) - "Moreover, CBL treatment increased arborization in both normotensive and hypertensive rats in the CA1, and DG regions of hippocampus and EC and selectively increased spine density in the hippocampus of hypertensive rats. These findings suggest that CBL neurotrophic treatment enhances recognition memory and promotes dendritic growth or spine density, depending on the neurochemical environment within the brain."

Journal • Preclinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension

Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis. (PubMed, Front Neurosci) - "The interventions assessed included Cerebrolysin, Citicoline, Edaravone, Edaravone Dextranol, Human urinary kallidinogenase, Minocycline, Nerinetide, Butylphthalide, Vinpocetine, and Control. To further validate the efficacy and safety of neuroprotective agents, future studies should involve larger sample sizes and conduct multicenter, large-scale randomized controlled trials. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=601346, identifier CRD42024601346."

Journal • Retrospective data • Review • Cardiovascular • Ischemic stroke

The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. (PubMed, Neuroscience) - "Thus, this review aims to discuss the possible therapeutic efficacy of CBL in the management of VD. In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Inflammation • Vascular Neurology

Cerebrolysin in Patients Diagnosed with Subarachnoid Hemorrhage-The Results of an Observational Cohort Study. (PubMed, Biomedicines) - "We examined the correlation between Cerebrolysin administration and additional Amantadine treatment or neuromonitoring, craniectomy, and endovascular treatment and its impact on the Glasgow Outcome Scale (GOS) score, length of stay (LOS), and mortality. It does not affect the raw values of GOS or LOS in patients with SAH. Further studies with larger patient groups are needed to investigate the role of Cerebrolysin as an additional treatment in SAH."

Journal • Observational data • Hematological Disorders • Subarachnoid Hemorrhage

The effectiveness of olfactory training for chronic olfactory disorder following COVID-19: a systematic review. (PubMed, Front Hum Neurosci) - "Integrating olfactory training with adjuvants like CoUltraPEALut, Cerebrolysin, and oral Vitamin A has demonstrated substantial benefits in enhancing post-COVID-19 olfactory function. Strict adherence to the OT protocol and extending the duration of OT to 3 months or more significantly enhance treatment outcomes."

Journal • Review • Infectious Disease • Novel Coronavirus Disease

Cerebrolysin Induces Motor Recovery Along with Plastic Changes in Motoneurons and an Increase in GAP43 Protein in the Ventral Spinal Cord Following a Kainic Acid Excitotoxic Lesion in the Rat Motor Cortex. (PubMed, Neurochem Res) - "There was also a significant increase in GAP43 protein, suggesting that CBL may promote plastic changes through this protein, among others. Hence, this study proposes that cerebrolysin could promote motor recovery following motor cortex lesions by driving neuronal changes and dendritic spine plasticity on motoneurons and an increase in GAP43 protein, along with other mechanisms."

Journal • Preclinical

Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. (PubMed, Front Pharmacol) - "The total sample size was 18,423 cases and included nine interventions: citicoline, edaravone (EDV), edaravone dexborneol, cinepazide maleate, cerebrolysin, minocycline, ginkgolide, ginkgo diterpene lactone meglumine (GDLM), and conventional (CON) treatment. Moreover, ginkgolide, EDV, edaravone dexborneol, and GDLM treatment schemes revealed not only a high total treatment effective rate but also a low rate of treatment inefficacy. When considering the combination of the total treatment effective rate with adverse effect, EDV, ginkgolide, and edaravone dexborneol were revealed as the safest and most effective."

Journal • Retrospective data • Review • Cardiovascular • Ischemic stroke

Evaluating the Effectiveness of Neuroprotective Strategies in Enhancing Post-stroke Recovery: A Systematic Review of Meta-Analyses and Clinical Trials. (PubMed, Cureus) - "This systematic review evaluates the effectiveness of various neuroprotective strategies in enhancing recovery following acute ischemic stroke, focusing on interventions such as normobaric oxygen (NBO), lithium, selective serotonin reuptake inhibitors (SSRIs), and Cerebrolysin...SSRIs, particularly fluoxetine, showed moderate success in improving motor recovery, as evidenced by the FLAME (Fluoxetine for Motor Recovery after Acute Ischaemic Stroke) trial and meta-analyses...These findings emphasize the mixed efficacy of these neuroprotective interventions and underscore the necessity for personalized treatment protocols and further large-scale, controlled trials to clarify their roles in clinical practice. This review contributes to the ongoing dialogue on optimizing post-stroke recovery and highlights the critical need for evidence-based neuroprotective strategies."

Journal • Review • Cardiovascular • Ischemic stroke

Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review. (PubMed, Curr Allergy Asthma Rep) - "Nine treatment groups were analysed, including olfactory training, local and systemic corticosteroids, platelet-rich plasma (PRP), calcium chelators, vitamin supplements including palmitoylethanolamide with luteolin, insulin, gabapentin and cerebrolysin. Primary objective was the effect of the studied treatments on the delta olfactory function score (OFS) for objective/psychophysical testing. Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction."

Journal • Review • Infectious Disease • Novel Coronavirus Disease

Cerebrolysin in Critically Ill Patients With Delirium (clinicaltrials.gov) - P=N/A | N=500 | Enrolling by invitation | Sponsor: Medical University of Lublin

New trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders